POMALYST (POMALIDOMIDE) LABEL UPDATE NOW AVAILABLE
- FLASCO
- July 9, 2015
- Drugs
POMALYST (POMALIDOMIDE) LABEL UPDATE NOW AVAILABLE
Celgene Corporation releases new phase 3 clinical trail information for Pomalyst. POMALYST (pomalidomide) + low-dose dexamethasone(dex) delivered significantly longer progression-free survival (PFS) vs high-dose dex in a phase 3 clinical trial. Pomalyst is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
